The company acquired dialysis businesses during the six months ended June 30, 2024, contributing to revenue growth. This indicates a strategy of inorganic growth, but the long-term success depends on successful integration.

The company is continuing its strategic review of outpatient clinic capacity, which has resulted in higher than normal charges for center capacity closures. This suggests a focus on optimizing the existing asset base, but it also entails associated costs.

The company's international dialysis operations provided dialysis and administrative services through 452 outpatient dialysis centers located in 13 countries outside of the United States. This demonstrates a commitment to global expansion.

Management is implementing cost-saving initiatives designed to help mitigate cost and volume pressures. This indicates proactive management in response to challenging economic conditions.

The CEO and CFO concluded that the company's disclosure controls and procedures were effective as of June 30, 2024. This provides assurance regarding the reliability of financial reporting.

Management suspended all claims processing activity with Change Healthcare (CHC) due to a cybersecurity breach that affected Change Healthcare (CHC). This indicates management's ability to address the issue.

The cybersecurity breach at Change Healthcare (CHC) caused a significant reduction in cash flow during the first and second quarters of 2024. This highlights the risk of reliance on third-party service providers and the potential for disruptions.

Elevated mortality rates of patients are negatively impacting revenue and treatment volume. This poses a significant risk to the company's financial performance.

The company faces risks from potential changes in laws, regulations, and requirements, including those related to healthcare and antitrust matters. This highlights the uncertainty and potential for adverse impacts from regulatory changes.

The company faces increased competition from dialysis providers and others. This increased competition may result in decreased market share.

The company faces risks from new or potential entrants in the dialysis and pre-dialysis marketplace and potential impact of innovative technologies, drugs, or other treatments on the dialysis industry. This poses a risk to the company's competitive position.

The company faces risks arising from potential changes in or new laws, regulations or requirements applicable to us, including, without limitation, those related to healthcare, antitrust matters, including, among others, non-competes and other restrictive covenants, and acquisition, merger, joint venture or similar transactions and/or labor matters, and potential impacts of changes in enforcement thereof or related litigation impacting, among other things, coverage or reimbursement rates for our services or the number of patients enrolled in or that select higher-paying commercial plans, and the risk that we make incorrect assumptions about how our patients will respond to any such developments. This poses a risk to the company's competitive position.

Charges for U.S. dialysis center closures increased operating expenses, indicating efforts to optimize the clinic footprint but also highlighting associated costs. The company expects center closure rates to remain at elevated levels over the remainder of 2024.

Ongoing global economic conditions and political and regulatory developments, such as general labor, supply chain and inflationary pressures have increased, and will likely continue to increase, our expenses, including, among others, staffing, labor, and supply costs. This poses a risk to the company's operational efficiency.

The company is increasing its use of third-party service providers to perform certain activities. This indicates a focus on cost efficiencies, but it also introduces risks related to reliance on external parties.

The company is subject to noncompliance by us or our business associates with any privacy or security laws or any security breach by us or a third party, such as the recent cyberattack on CHC, including, among other things, any such non-compliance or breach involving the misappropriation, loss or other unauthorized use or disclosure of confidential information. This poses a risk to the company's operations.

The company is investing in information technology. These investments are designed to help mitigate cost and volume pressures.

The company is implementing telemedicine. This is part of the company's strategy with respect to IKC and VBC initiatives and home based dialysis in the desired time frame and in a complex, dynamic and highly regulated environment.

The company repurchased shares of its common stock. This indicates management's view that shares are undervalued and demonstrates confidence in future cash flow generation.

The company acquired dialysis businesses during the six months ended June 30, 2024. This indicates a strategy of inorganic growth.

The company had capital expenditures to maintain the productive capacity of the business and include those made for investments in information technology, dialysis center renovations, capital asset replacements, and any other capital expenditures that are not development or acquisition expenditures. The company also had development capital expenditures principally represent capital expenditures (other than acquisition expenditures) made to expand the productive capacity of the business and include those for new U.S. and international dialysis center developments, dialysis center expansions and relocations, and new or expanded contracted hospital operations. This indicates that the company is investing in its operations.

The company has aspirations, goals and disclosures related to environmental, social and governance (ESG) matters, including, among other things, evolving regulatory requirements affecting ESG standards, measurements and reporting requirements. This indicates a commitment to ESG.

Developments in general economic and market conditions have directly and indirectly impacted the Company and in the future could have a material adverse impact on our patients, teammates, physician partners, suppliers, business, operations, reputation, financial condition, results of operations, share price, cash flows and/or liquidity. This indicates a risk to the company's operations.

Certain of these impacts could be further intensified by concurrent global events such as the ongoing conflicts between Russia and Ukraine and in Israel, Gaza and the surrounding areas, which have continued to drive sociopolitical and economic uncertainty across the globe. This poses a risk to the company's operations.

The company faces our ability to attract, retain and motivate teammates and our ability to manage operating cost increases or productivity decreases whether due to union organizing activities, legislative or other changes, demand for labor, volatility and uncertainty in the labor market, the current challenging and highly competitive labor market conditions, or other reasons. This poses a risk to the company's operations.